Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Fineline Cube Feb 8, 2025

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...

Company Drug

Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis

Fineline Cube Feb 8, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...

Company Drug

Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference

Fineline Cube Feb 8, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...

Company

RemeGen’s Executive Director He Ruyi Resigns for Career Development

Fineline Cube Feb 8, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study

Fineline Cube Feb 8, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Feb 8, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...

Company Drug

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Fineline Cube Feb 8, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Company Medical Device

Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth

Fineline Cube Feb 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its results for the first quarter of fiscal...

Company Drug

Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA

Fineline Cube Feb 8, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...

Company Deals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Fineline Cube Feb 8, 2025

Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...

Company Deals

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Fineline Cube Feb 7, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...

Company

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches

Fineline Cube Feb 7, 2025

China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...

Company

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products

Fineline Cube Feb 7, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...

Company Drug

CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA

Fineline Cube Feb 7, 2025

China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...

Company Drug

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS

Fineline Cube Feb 7, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...

Company Drug

Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease

Fineline Cube Feb 7, 2025

China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...

Company Drug

Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL

Fineline Cube Feb 7, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...

Company Drug

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study

Fineline Cube Feb 7, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...

Company Drug

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer

Fineline Cube Feb 7, 2025

Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...

Company Drug

Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease

Fineline Cube Feb 7, 2025

Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...

Posts pagination

1 … 269 270 271 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.